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We examined faecal egg count reduction tests (FECRTs) conducted with hookworm-infected humans in
Ghana in 2007 (study 1) and 2010 (study 2) in order to explore aspects of the test analysis. Some subjects
showed increased FEC following drug treatment. This occurred mostly in <150 epg pre-treatment FEC
subjects. We sought a means to remove ‘erroneous’ negative drug efﬁcacy cases from the FECRT analysis.
Pre- and post-treatment FECs from negative drug efﬁcacy cases were examined to determine whether
they represented replicates from a single randomly distributed sample, that is, if they were consistent
with a Poisson distribution. Cases where the post-treatment FEC was greater than that expected if it
and the pre-treatment sample had been taken from a single random distribution of eggs were excluded
from the FECRT. We suggest that these cases most likely represent non-random distribution of eggs in
stools, day-to-day variations in egg excretion, or worm patency onset after drug treatment, and hence
are not accurate measurements of drug efﬁcacy. This led to exclusion of the most extreme negative drug
efﬁcacy cases, with signiﬁcant increases in overall drug efﬁcacy for study 1 (81.6% vs 89.2%) and study 2
(86.7% vs 89.4%). Excluding FEC <150 individuals from the analysis also increased the study 1 efﬁcacy
(81.6% vs 88.9%), however, this resulted in the exclusion of 45% of the study subjects, compared to the
exclusion of just 5% using the Poisson distribution method. While low FEC subjects are excluded from
livestock FECRTs, the signiﬁcant prevalence of such subjects in human FECRTs suggests that their exclu-
sion may not be practical. Hence, we suggest that the inﬂuence of low FECs can be minimised by exclud-
ing ‘erroneous’ negative efﬁcacy cases using a simple Poisson distribution analysis.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction the only current means to monitor drug sensitivity in the ﬁeld isWith the implementation of mass drug administration pro-
grammes for the control of human soil transmitted helminths
(STHs) there is increasing interest in ensuring that drug resistance
can be detected should it emerge. While some in vitro bioassay and
molecular-based methods for testing drug sensitivity have been
examined with reference to STHs and benzimidazole drugs (for
example, Albonico et al., 2004, 2005; Diawara et al., 2009; Kotze
et al., 2009; Humphries et al., 2013) they are yet to be validated
as useful tools for resistance detection in ﬁeld settings. Hence,the faecal egg count reduction test (FECRT). This test involves a
comparison of faecal egg counts (FECs) in human subjects pre-
and post-drug treatment. While such tests have been used for
many years in the livestock health sphere to examine changes in
drug sensitivity in gastrointestinal parasites, they have only more
recently been applied to human STHs. Consequently, a number of
recent reports have examined aspects of their design, and made
recommendations as to how the tests should be used for human
STHs (Levecke et al., 2011a,b; Vercruysse et al., 2011a,b), and the
WHO has recently issued revised guidelines for assessing drug efﬁ-
cacy against schistosomiasis and STHs (WHO, 2013).
One feature of livestock FECRTs is the recommendation to ex-
clude animals with low FEC for statistical reasons (Presidente,
1985; Coles et al., 2006), as low FECs are not accurately measured
with existing egg counting techniques which lack sensitivity. The
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and 100 for cattle (FECs are usually lower in cattle than in the other
species). Satisfying this constraint for inclusion does not generally
present a great difﬁculty in terms of recruitment of suitable ani-
mals for livestock studies. However, subject recruitment and com-
pliance issues are more difﬁcult in the human ﬁeld than for
livestock drug efﬁcacy studies. The difﬁculty in recruiting suitable
individuals for human FECRTs is further exacerbated by the high
prevalence of subjects with low infection levels at some ﬁeld sites
described in recent reports; for example, over the seven ﬁeld sites
described by Vercruysse et al. (2011a), human subjects with light
hookworm infections (that is, epg < 1999, from Montresor et al.,
1998) made up 94% of the total number of infections. Further,
the proportion of the total study populations at the various sites
that had FEC < 150 varied from 6% in Brazil, up to 49% in Cameroon,
and 67% in Vietnam. Hence, it may be far more difﬁcult to adhere
to a FEC > 150 inclusion limit for human FECRTs compared to the
relative ease of following this rule in livestock FECRTs.
Vercruysse et al. (2011a) reported on the inﬂuence of inclu-
sion of low pre-treatment subjects on human FECRT data. They
found that drug efﬁcacy calculated as the mean of the FECRs
in individual study subjects was highly affected by excluding
subjects with pre-treatment FECs of <150. However, the inclu-
sion of FEC <150 subjects did not affect the FECRT outcomes at
each of their seven ﬁeld sites when the FECR was calculated
on the basis of group means. This indicated that, for their data
sets, the responses of the low FEC subjects did not distort the
overall study outcomes as long as the analysis was performed
at the group level. However, in demonstrating the signiﬁcant ef-
fect of low FEC subjects on FECRT outcomes when calculated
using individual FECRs, this study indicated the potential for
the inﬂuence of low FEC subjects to be signiﬁcant in terms of
the group mean-based FECR if they reached dominant propor-
tions in a study population.
As a part of ongoing efforts to reﬁne human STH FECRTs in
order to ensure that they are reproducible, and hence will be
able to detect changes in drug sensitivity over time, we aimed
to assess the inﬂuence of low pre-treatment FECs on the analysis
of data from two recently conducted human hookworm FECRTs.
We examined data sets collected during trials of albendazole
against human hookworms conducted in Ghana in 2007 and
2010 (Humphries et al., 2011, 2013). These studies were of inter-
est as they had been carried out in populations dominated by
subjects with low infection intensities (from Montresor et al.,
1998). We compared three different analytical approaches for
estimating drug efﬁcacy from FECRTs: (a) group FEC averages,
(b) group averages excluding subjects with pre-treatment FEC
less than 150 epg, and (c) group averages after the use of a
Poisson distribution method to identify and exclude subjects
with ‘erroneous’ negative drug efﬁcacy values. We also utilized
duplicate egg counts from the 2010 ﬁeld study in order to exam-
ine the variability in FEC at low infection intensities.2. Materials and methods
2.1. FECRT data
We examined data from two recent FECRTs conducted in Kin-
tampo North Municipality, Ghana. The studies were denoted ‘study
1’ (conducted in 2007, Humphries et al., 2011) and study 2 (con-
ducted in 2010, Humphries et al., 2013). Both studies were ap-
proved by the Yale Human Investigations Committee and the
Institutional Review Board of the Noguchi Memorial Institute for
Medical Research (NMIMR) at the University of Ghana. The two
studies are summarised below:(i) Study 1: Egg counts were performed on 258 subjects using
the Kato–Katz method (WHO, 1996) on single faecal samples
from each subject (egg count sensitivity of 37). Positive
counts were recorded for 116 subjects, and 102 of these
were treated with albendazole. Post-treatment feacal
samples were received from 95 subjects during the period
14–21 days after the drug treatment.
(ii) Study 2: Egg counts were performed on duplicate faecal
samples received from 258 subjects using the Kato-Katz
method (WHO, 1996) (egg count sensitivity of 24, with
two replicate samples per subject, i.e. for the total eggs
counted per subject 1 egg = 12 epg). At least one positive
count was recorded for 121 subjects, and all of these were
treated with albendazole. Duplicate follow up samples were
requested from all subjects, and received from 94 subjects
during the period 14–21 days after the drug treatment. At
least one follow up sample was received from 112 subjects.
A total of 84 subjects provided two pre- and two post-treat-
ment samples and were therefore used in the subsequent
FECRT analysis.
2.2. Infection intensity
We examined the infection intensities across subjects in Studies
1 and 2 by subdividing the pre-treatment FEC data into infection
intensity classes according to the criteria of Montresor et al.
(1998) for human hookworms: light, 1–1999 epg, moderate
2000–3999, and high >3999. In addition, we applied a further sub-
division of the light infection category into <150 and 150–1999 as
the <150 group was of particular interest given the WAAVP guide-
lines for exclusion of animals with FEC <150 from livestock FECRTs
(described by Coles et al., 2006).
2.3. Analysis of drug efﬁcacy
FECRT outcomes for both studies were determined using the R
package ‘‘eggCounts’’ (Paul, 2013) via the user friendly web inter-
face at http://www.math.uzh.ch/as/?calc. The approach is based
on Bayesian methods, and assumes ﬁrstly that the observed egg
count is subject to Poisson errors (magniﬁed by the dilution factor),
and secondly that the between animal counts are over dispersed
(negative binomial or zero inﬂated). The user enters the pre-treat-
ment and post-treatment FECs, and the dilution factor used to cal-
culate the FECs. Bayesian inference is done via Markov chain Monte
Carlo sampling. The output includes the FECR with 95% Conﬁdence
Intervals (CIs).
We examined the FECRT data using, (a) the full data sets from
studies 1 and 2, as well as, (b) in separate groups showing pre-
treatment FECs of < or >150 epg, as we were interested speciﬁcally
in the effect of excluding FEC <150 epg individuals on the FECRT
outcomes. Within study 1 or study 2, drug efﬁcacies derived from
these different groups were considered to be signiﬁcantly different
if their 95% CIs did not overlap.
2.4. Poisson distribution quality control test for negative drug efﬁcacy
data
We utilised a Poisson distribution-based method (modiﬁed
from Torgerson et al., 2012) to examine cases in which drug efﬁ-
cacy was negative (FEC increased after drug treatment) as a means
of applying a quality control measure to the data set. The FEC re-
sults for individual subjects at the pre- and post-treatment time
points (n = 2 for study 1, and n = 4 for study 2) were analysed to
determine if the group of two or four values for each subject fol-
lowed a Poisson distribution. The index of dispersion (ID = vari-
ance/mean) was calculated for each subject, and then compared
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replicate egg counts from a single faecal preparation in which the
distribution of eggs followed a Poisson distribution. The subjects
whose ID was greater than this maximum value were omitted from
the FECRT analysis. The FECRT outcomes for Studies 1 and 2 after
application of this method were compared to the drug efﬁcacy
outcomes for the full data set, as well as for the < or >150 epg
pre-treatment FEC groups.
2.5. Egg count variability
In order to examine the degree of variability among replicate
FECs, and particularly the relationship between the degree of var-
iability and the infection intensity, we calculated the coefﬁcient of
variation (CV = the standard deviation/mean, expressed as a per-
centage) for FECs conducted on repeat samples taken from each
study 2 subject pre- and post- drug treatment. All subjects who
had recorded two FECs, with at least one being greater than zero,
were included in this analysis. Some subjects who had submitted
two pre-treatment samples, but less than two post-treatment sam-
ples (and hence were not included in the FECRT analysis) were in-
cluded here in terms of their pair of pre-treatment FECs alone. In
addition, many subjects who were included in the FECRT analysis
showed two zero counts at the post-treatment time point and so
were not included in this analysis of egg count variability. Hence,
the data set for this analysis did not correspond directly to the FEC-
RT data set. The number of pairs of FECs that were analysed here
was 158 (102 pairs of pre-treatment samples, and 56 pairs of
post-treatment samples).Fig. 1. Distribution of pre-treatment FECs in study subjects for study 1 (A) and
study 2 (B). The ranges shown on the X-axis correspond to the three infection
intensities described by Montresor et al. (1998) (light 1–1999, moderate 2000–
3999 and high >3999) with a further subdivision of the light group into < or
>150 epg FEC groups.3. Results
The distribution of pre-treatment FECs in the subjects from stud-
ies 1 and 2 are shown in Fig. 1. Both studieswere dominated by sub-
jects in the light infectioncategory (FEC<1999, fromMontresoret al.,
1998), with a large number of FECs <150 in both studies (45% of the
total in study 1, Fig. 1A; 39% of the total in study 2, Fig. 1B).
Table 1 shows the studies 1 and 2 drug efﬁcacy results for the
whole data sets, after division into < or >150 pre-treatment FEC
subjects, and after application of the Poisson distribution exclusion
criterion. Drug efﬁcacy values, as measured by FECR, for the group
of <150 FEC subjects from both studies were very low (negative for
study 1, and 52.8% for study 2). The study 1 drug efﬁcacy showed a
signiﬁcant increase from 81.6% to 88.9% after exclusion of the 43
subjects (45% of the study subjects) with a pre-treatment FEC of
<150. For study 2, the exclusion of the 33 < 150 epg FEC subjects
(39% of the study subjects) did not have a signiﬁcant effect on
the FECR (86.7% vs 88.6%). The application of the Poisson distribu-
tion test to study 1 (the identiﬁcation of the speciﬁc subjects
excluded for this analysis is described below) resulted in a signiﬁ-
cant increase in the FECR compared to the whole data set (81.6% vs
89.2%) while only excluding ﬁve subjects (5% of the study subjects)
from the analysis. Similarly, the Poisson distribution test resulted
in a signiﬁcant increase in drug efﬁcacy for study 2 (86.7% vs
89.4%) with the exclusion of four subjects (5% of the study subjects)
from the analysis.
The relationship between drug efﬁcacies and pre-treatment FEC
for each individual study subject is illustrated in Fig. 2A. While
many subjects showed a drug efﬁcacy of 100% (FEC reduced to zero
after drug treatment) (61% for study 1, and 40% for study 2) a large
number showed much lower efﬁcacy values. Many subjects
showed an increase in FEC after treatment compared to their
pre-treatment value (drug efﬁcacy < 0%). These cases were all asso-
ciated with pre-treatment FECs of <1000. There was a clear trend to
a greater presence of low drug efﬁcacy values as the pre-treatment
FEC decreased, with most of these cases occurring for the <150 FEC
subset. The most extreme cases showed efﬁcacies of less than
1000%, representing over 10-fold increases in post-treatment
FEC compared to the pre-treatment value.
Index of dispersion (ID) values were calculated using the pre-
and post-treatment FECs for each of the study subjects who had
shown an increase in FEC after drug treatment (from Fig. 2A). These
ID values are shown in Table 2 for the thirteen study 1 subjects,
and seven study 2 subjects who had shown a negative drug efﬁ-
cacy. A comparison of ID values with the expected Poisson distri-
bution limits indicated that the variation in FEC values for ﬁve
study 1 and four study 2 subjects was greater than that expected
from a random distribution. The FEC drug efﬁcacy data for these
study subjects is illustrated in Fig. 2B. The effect of excluding these
subjects on the overall study FECRT outcomes was described above
with reference to Table 1.
In order to explore possible explanations for the greater range
of FECRT outcomes shown by study subjects with low FEC (from
Fig. 2A) we examined the degree of variability in repeat egg counts
on separate faecal samples taken from the same study subjects.
Study 2 provided an opportunity for this analysis as two faecal
samples had been examined for each study subject both pre- and
post- drug treatment. Fig. 3 shows that the coefﬁcient of variation
(CV) for the pairs of FECs taken throughout the study increased as
the mean FEC decreased.4. Discussion
The present study has analysed data from two recent trials of
albendazole efﬁcacy against human hookworms in Ghana in order
Table 1
Drug efﬁcacy from Studies 1 and 2, calculated using whole data sets, and after division into < or >150 epg pre-treatment FEC groups, and after exclusion of negative efﬁcacy data
based on expected Poisson distribution sampling variation.
Study Data set Number of subjects Mean FEC (epg) Drug efﬁcacy, 95%% CIs (%)a
Pre-treatment Post-treatment
1 All data 95 735 137 81.6, 79.7 83.5 a
Pre FEC < 150 43 81 131 64.8, 108 29.1 b
Pre FEC > 150 52 1275 142 88.9, 87.2 90.6 c
After negative efﬁcacy exclusionsb 90 770 85 89.2, 87.8 90.6 c
2 All data 84 531 70 86.7, 85.4 87.9 a
pre FEC < 150 33 72 34 52.8, 39.5 63.6 b
pre FEC > 150 51 828 94 88.6, 87.4 89.7 ac
After negative efﬁcacy exclusionsb 80 550 58 89.4, 88.2 90.4 c
a Within a study, drug efﬁcacies followed by the same letter are not signiﬁcantly different, based on overlap of 95% CIs.
b Denotes adjustment of data by exclusion of subjects showing negative drug efﬁcacies in which pre- and post-treatment FECs did not lie within expected Poisson sampling
variation limits (see text for details).
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FECRTs. We applied a quality control measure to both data sets
in order to identify likely ‘erroneous’ data points, and hence to im-
prove our ability to accurately quantify drug efﬁcacy in these trials.
Application of this measure resulted in signiﬁcantly higher drug
efﬁcacy outcomes for both trials, with the removal of only about
5% of the study subjects from the analysis. This method should
be a useful quality control measure to apply to all human FECRT
data sets in order to ensure greater conﬁdence in FECRT outcomes.
This is particularly important as attention is currently focused on
maximising the reproducibility of human FECRTs in order to allow
conﬁdence in comparing the results across different geographical
areas, or time periods, in order to detect the emergence of drug
resistance (Levecke et al., 2011b; Vercruysse et al., 2011a, b).
We found that drug efﬁcacies were much lower in the groups of
subjects showing low pre-treatment FECs (<150 epg). However, the
impact of this on the FECRT outcome differed between the two
studies: in study 1 omission of <150 FEC subjects had a signiﬁcant
impact on the drug efﬁcacy (81.6% for all data, vs 88.9% for >FEC
150 group), while for study 2 there was no signiﬁcant difference
between the two efﬁcacy values (86.7% for all data vs 88.6% for
>FEC 150 group). This comparison of studies 1 and 2 is informative
as to the potential impact of low FEC subjects on interpretation of
whether a FECRT outcome may be indicative of the presence of
drug resistance. In study 1 the interpretation of the study outcome
may be quite different depending on whether the low FEC subjects
are included: while the value of 88.9% (<150 FEC excluded) is com-
parable to the hookworm drug resistance threshold of 90% recom-
mended by Vercruysse et al. (2011b) and the WHO (2013), and
may therefore not trigger concern as to the presence of resistance,
the value of 81.6% (<150 FEC included) is more suggestive of the
presence of drug resistance in the population.
This contrast between the two studies in terms of the impact of
exclusion of FEC <150 subjects indicates that the impact of low
FECs on the overall FECRT outcome in different studies will not
be easy to predict. Both studies 1 and 2 had a similar percentage
of subjects with FEC <150 (45% for study 1, and 39% for study 2),
however, the most extreme cases of FEC increases following drug
treatment were seen in study 1 (Fig. 2). Hence, while the distorting
effect of the low FEC subjects in study 1 could be detected and
highlighted after the FECRT was complete, the effect could not be
predicted by simply noting the percentage occurrence of low
pre-treatment FECs in the study population. Vercruysse et al.
(2011a) found that exclusion of <150 subjects had very little effect
on mean group drug efﬁcacy results in Vietnam (remained at 100%)
and Cameroon (changed from 93.0% to 93.6%) despite these sites
having 67% and 49%, respectively, of the study subjects showing
FEC <150. Hence, the distortion of FECRT outcome by low FEC
subjects seen in study 1 was not observed at the Vietnam andCameroon sites despite the low FEC subjects forming a larger per-
centage component of the study populations at these two sites.
A signiﬁcant number of study subjects showed increases in FEC
following drug treatment (14% in study 1, and 8% in study 2). These
cases occurred mostly in the <150 FEC subjects. The spectra of ef-
fects of a drug treatment range from complete removal of a worm
population from an infected host, to having no effect on the popu-
lation. Hence, cases where FEC increases following treatment are
not a reﬂection of the drug action, but rather are most likely related
to inaccurate egg counting techniques (low sensitivity, variability
due to Poisson distribution effects, discussed below), non-random
distribution of eggs in stools at low infection levels (discussed be-
low), worm biology (for example, day-to-day variation in egg
excretion, the onset of patency, discussed below), or a laboratory
error (mislabelling etc). These cases therefore do not represent
the effects of the drug against the worm population, and hence
we believe that they should not be included in a FECRT which aims
to accurately measure drug efﬁcacy.
We therefore sought a means to examine a FECRT data set with
a view to determining if speciﬁc instances of increased FEC follow-
ing drug treatment should be excluded from the study. We suggest
that one means to address this issue is to apply a modiﬁcation of
the quality control measure proposed by Torgerson et al. (2012)
for replicate egg counts on single faecal preparations. FECs based
on repeat samples from thoroughly mixed faecal suspensions are
expected to be variable due to the Poisson distribution of eggs in
the suspension (Torgerson et al., 2012). These authors describe a
means to determine if such replicate measurements from a single
faecal preparation follow a Poisson distribution. If the replicate val-
ues did not satisfy this criterion, the authors argued that they rep-
resented samples from a non-random distribution, and therefore
that there had been a problem with sample processing, mixing or
counting, and, hence, that data set should be discarded, and the
counts repeated. We have applied this test across pre- and post-
treatment samples from individuals rather than to replicate egg
counts from a single faecal preparation as described by Torgerson
et al. (2012). We have considered repeat samples from the same
subject at different time points to simulate repeat samples from
a single faecal preparation that may be expected if the worm pop-
ulation in the host does not change in response to the drug, that is,
if the drug has a zero efﬁcacy. If the worm population in the host is
unchanged, and hence their egg output is also unchanged, the con-
centration and distribution of eggs in the pre-treatment sample
should be equivalent to the post-treatment sample, assuming that
the distribution in the stool at both time points is random.
We sought to be able to distinguish between those subjects
whose FEC increased by a magnitude within expectations of a Pois-
son distribution (hence the two time points represented replicates
from a single randomly distributed sample) as distinct from those
Fig. 2. Relationship between pre-treatment FEC and drug efﬁcacy for individual
subjects examined in studies 1 and 2; (A) all data from the two studies; (B) effect of
the Poisson distribution test for negative drug efﬁcacy subjects on the FECRT data
sets; data points that would be excluded from the FECRT analysis using the Poisson
distribution sampling variation limits across pre- and post-treatment FECs are
indicated with an X (see text for details).
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pected if the repeat samples followed such a distribution. We ap-
plied this test to all subjects who had showed an increase in FEC
following the drug treatment. Subjects whose repeat samples did
not follow the expected distribution were excluded from the FECRT
analysis as we suggest that the observed increase in FEC represents
the result of an inﬂuence other than drug action (e.g., non-random
distribution of eggs in the stool, labelling or mixing error, day-to-
day egg excretion variability, onset of patency). This resulted in
the most extreme cases of negative drug efﬁcacy being removed
from the overall FECRT data set (from Fig. 2B), with a signiﬁcant
impact on the FECRT outcome for both studies 1 and 2 (Table 1).
Notably, the subject showing the greatest percentage increase in
FEC after drug treatment in study 2 (from Fig. 2B, subject 59032
from Table 2) was not removed from the analysis using this meth-
od. However, their inclusion would be expected to have little con-
sequence on the FECRT outcome as the FEC for this subject was so
low as to have little or no impact on the overall FECRT result on a
group basis.We suggest that this test is an appropriate quality control mea-
sure to apply to subjects showing increased post-treatment FEC in
human FECRTs. It is very simple to apply as it is done after the col-
lection of all ﬁeld data. ID values are calculated using the mean and
variance of the pre- and post-treatment FECs for the individual
subjects who show increased FEC following the drug treatment,
and then these values are simply compared to ID values shown
in a single reference Table in order to assess whether the repeat
(pre- and post-treatment) FECs follow a Poisson distribution. The
test cannot be applied to subjects whose FEC decreases following
drug treatment, no matter how small the difference, as such an ef-
fect could be due to drug action, and hence the pre- and post-treat-
ment samples would not be expected to represent replicates from a
random distribution.
Interestingly the impact of applying this quality control method
was similar to the outcome of the analysis in which <150 FEC sub-
jects were omitted (88.9% vs 89.2% for study 1, and 88.6% vs 89.4%
for study 2). However, the Poisson analysis resulted in the exclu-
sion of only ﬁve subjects from the study 1 data set, and four from
the study 2 data set, compared to exclusions of 43 and 33 subjects
from studies 1 and 2 if the <150 epg pre-treatment FEC exclusion
criterion was applied.
Two early human hookworm studies speciﬁcally examined the
distribution of eggs in human stools by comparing the variability in
egg counts from replicate samples from single stools (eggs counted
using the smear method) to the variability in replicate samples
from a single thoroughly mixed faecal suspension from each stool
(the dilution method from Stoll, 1923) (Beaver, 1949; Melvin et al.,
1956). Beaver (1949) found that the variability was similar for the
two types of measurements, suggesting a random distribution of
eggs in the stool. Melvin et al. (1956) found that both the replicate
smear method counts from single stools, and the replicate dilution
method counts from single faecal slurries, followed a Poisson dis-
tribution (based on index of dispersion values), indicating that
the eggs were also distributed in a random manner in the faeces
of their study subjects. However, importantly these studies utilised
human subjects with FEC >1000 epg in the case of Melvin et al.
(1956) and at least 1000 eggs per ml in the study of Beaver
(1949), that is, signiﬁcantly higher than many of the pre-treatment
FECs recorded from the Ghanaian subjects in studies 1 and 2.
Hence, while the early studies indicate that the potential source
of variation in FEC data due to non-randommixing of human hook-
worm eggs in stools may not be signiﬁcant when the FECs are
above 1000 epg or 1000 eggs per ml, the potential remains for
them to be more signiﬁcant for low FEC subjects that dominated
the studies 1 and 2 populations. It may be expected that there is
an increased likelihood of a non-random distribution of eggs in
the stool as the egg count decreases to very low levels. Egg produc-
tion may become limited to more discrete intervals of time and
location within the intestine when only a low number of adult fe-
males are present. Hence, two sources of variability associated
with low egg counts are expected to be present, with one certainly
expected to become more important as the FEC decreases (varia-
tion due to Poisson sampling errors, assuming a random distribu-
tion of eggs in the stool), and the other also potentially becoming
important as egg counts decrease (due to possible non-random
mixing of eggs in the stool).
Another possible explanation for the low drug efﬁcacy values
observed in some individuals, and negative efﬁcacies in others, is
that some hookworms which survived the drug treatment only
reached patency after the pre-treatment sampling time. In this
way they would not have contributed to the eggs present in the
pre-treatment sample, but may have contributed signiﬁcantly to
the post-treatment sample. This is an unavoidable issue with hu-
man FECRTs in environments where there is signiﬁcant transmis-
sion occurring at all times in the study population. The impact of
Table 2
Application of Index of Dispersion (ID) analysis to pre- and post-treatment raw egg count data from subjects showing increased FEC after the drug treatment.
Subject Pre-treatment raw egg count Post-treatment raw egg count IDa To be excluded from studyb
Study 1
1013d 2 61 55.3 ⁄
1016c 3 4 0.14
1020b 5 29 16.9 ⁄
1020c 1 11 8.33 ⁄
1029a 5 6 0.09
1057c 2 4 0.67
1087d 4 7 0.82
1155c 25 34 1.37
2015a 16 20 0.44
2015e 3 21 13.5 ⁄
2137c 4 8 1.33
3086b 1 23 20.2 ⁄
3249c 1 2 0.33
Study 2
23002 6 20 10 36 9.93 ⁄
28035 2 3 10 2 3.51 ⁄
30021 8 6 4 11 1.23
30055 2 0 3 0 1.8
59003 7 5 31 0 17.8 ⁄
59032 1 0 2 2 0.73
74083 1 7 12 3 4.1 ⁄
a ID = Index of dispersion = variance/mean.
b Exclusion based on comparison to maximum ID values expected for Poisson-distributed data (from Torgerson et al., 2012).
Fig. 3. Relationship between mean FEC on stools collected from individual study 2
subjects on different days and the coefﬁcient of variation; each data point
represents mean ± SE, n = number of study subjects represented by each data
point; data points labelled with a different letter are signiﬁcantly different at
P = 0.05; the X-axis classes were set to give comparable numbers of subjects in each
subset.
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than those with high FECs as the onset of patency in a given num-
ber of worms in these two types of subjects will be more signiﬁcant
in terms of its magnitude relative to the pre-treatment egg excre-
tion rate in the subjects which showed only a low egg output be-
fore the drug treatment. The FECRT can only measure efﬁcacy
against egg laying worms at the time of treatment and provides
no information on efﬁcacy against developing stages.
While exclusion of animals with FEC <150 is recommended for
livestock FECRTs, such a criterion has not been applied strictly to
human studies, largely because of the difﬁculties associated with
recruiting enough study subjects with sufﬁciently high FECs for
such studies. The present study has illustrated the impact that
inclusion of low FEC subjects may have on a FECRT outcome,
particularly with study 1. This issue has the potential to become
even more important as ongoing mass drug administrationprogrammes, alongside health education and improved sanitary
conditions, reduce infection levels in areas where the possible
emergence of resistance will need to be monitored (Humphries
et al., 2012). That is, the testing for resistance will become more
problematic as drug treatments continue over time. As suggested
by several authors (Knopp et al., 2011; Levecke et al., 2011b,c;
Torgerson et al., 2012) one means to overcome this is to increase
the sensitivity of the counting technique (for example, counting
more McMaster slide chambers, or using FLOTAC) such that a
count of 150 represents the observation of many more eggs in
the counting procedure. In this way, the application of a >150
FEC cut-off for inclusion in a study becomes less relevant as the
sensitivity of the egg counting increases. The greater impact of
low FEC subjects observed in study 1, with an egg detection sensi-
tivity of 37, compared to study 2, with a sensitivity of 12, high-
lights this point. In addition, we suggest that the Poisson
distribution quality control measure described here is applied
across pre- and post-treatment samples for subjects showing neg-
ative drug efﬁcacies in order to remove ‘erroneous’ data points
from human FECRTs. The study subjects showing negative drug
efﬁcacies in studies 1 and 2 were mostly present in the <150 FEC
group, and hence, the adjustment proposed here may be one
means to at least partly counter the potentially distorting inﬂuence
of inclusion of low FEC study subjects in human FECRTs.
Acknowledgments
This work was supported by USA National Institutes of Health
Grant AI099623 and the Ghana–Yale Partnership for Global Health.
The authors would like to thank the ﬁeld research team at the
Noguchi Memorial Institute for Medical Research for technical
support, and the people of Kintampo North Municipality for their
participation. The authors have no conﬂicts of interest concerning
the work reported in this paper.
References
Albonico, M., Wright, V., Bickle, Q., 2004. Molecular analysis of the b-tubulin gene of
human hookworms as a basis for possible benzimidazole resistance on Pemba
Island. Mol. Biochem. Parasitol. 134, 281–284.
70 A.C. Kotze et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 64–70Albonico, M., Wright, V., Ramsan, M., Haji, H.J., Taylor, M., Savioli, L., Bickle, Q., 2005.
Development of the egg hatch assay for detection of anthelminthic resistance in
human hookworms. Int. J. Parasitol. 35, 803–811.
Beaver, P.C., 1949. Quantitative hookworm diagnosis by direct smear. J. Parasitol.
35, 125–135.
Coles, G.C., Jackson, F., Pomroy, W.E., Prichard, R.K., von Samson-Himmelstjerna, G.,
Silvestre, A., Taylor, M.A., Vercruysse, J., 2006. The detection of anthelmintic
resistance in nematodes of veterinary importance. Vet. Parasitol. 136, 167–185.
Diawara, A., Drake, L.J., Suswillo, R.R., Kihara, J., Bundy, D.A., Scott, M.E., Halpenny,
C., Stothard, J.R., Prichard, R.K., 2009. Assays to detect beta-tubulin codon 200
polymorphism in Trichuris trichiura and Ascaris lumbricoides. PLoS Negl. Trop.
Dis. 3, e397.
Humphries, D., Mosites, E., Otchere, J., Amoani Twum, W., Woo, L., Jones-Sanpei, H.,
Harrison, L.M., Bungiro, R.D., Benham-Pyle, B., Bimi, L., Edoh, D., Bosompem, K.,
Wilson, M., Cappello, M., 2011. Epidemiology of hookworm infections in
Kintampo North municipality, Ghana: patterns of malaria coinfection, anemia,
and albendazole treatment failure. Am. J. Trop. Med. Hyg. 84, 792–800.
Humphries, D., Nguyen, S., Boakye, D., Wilson, M., Cappello, M., 2012. The promise
and pitfalls of mass drug administration to control intestinal helminth
infections. Curr. Opin. Infect. Dis. 25, 584–589.
Humphries, D., Simms, B.T., Davey, D., Otchere, J., Quagraine, J., Terryah, S., Newton,
S., Berg, E., Harrison, L.M., Boakye, D., Wilson, M., Cappello, M., 2013. Hookworm
infection among school age children in Kintampo North Municipality, Ghana:
nutritional risk factors and response to albendazole treatment. Am. J. Trop. Med.
Hyg. 89, 540–548.
Knopp, S., Speich, B., Hattendorf, J., Rinaldi, L., Mohammed, K.A., Khamis, I.S.,
Mohammed, A.S., Albonico, M., Rollinson, D., Marti, H., Cringoli, G., Utzinger, J.,
2011. Diagnostic accuracy of Kato–Katz and FLOTAC for assessing anthelmintic
drug efﬁcacy. PLoS Negl. Trop. Dis. 5, e1036.
Kotze, A.C., Lowe, A., O’Grady, J., Kopp, S.R., Behnke, J.M., 2009. Dose–response assay
templates for in vitro assessment of resistance to benzimidazole and nicotinic
acetylcholine receptor agonist drugs in human hookworms. Am. J. Trop. Med.
Hyg. 81, 163–170.
Levecke, B., Behnke, J.M., Ajjampur, S.S., Albonico, M., Ame, S.M., Charlier, J., Geiger,
S.M., Hoa, N.T., Kamwa Ngassam, R.I., Kotze, A.C., McCarthy, J.S., Montresor, A.,
Periago, M.V., Roy, S., Tchuem Tchuenté, L.A., Thach, D.T., Vercruysse, J., 2011a. A
comparison of the sensitivity and fecal egg counts of the McMaster egg
counting and Kato–Katz thick smear methods for soil-transmitted helminths.
PLoS Negl. Trop. Dis. 5, e1201.Levecke, B., Speybroeck, N., Dobson, R.J., Vercruysse, J., Charlier, J., 2011b. Novel
insights in the fecal egg count reduction test for monitoring drug efﬁcacy
against soil-transmitted helminths in large-scale treatment programs. PLoS
Negl. Trop. Dis. 5, e1427.
Levecke, B., Rinaldi, L., Charlier, J., Maurelli, M.P., Morgoglione, M.E., Vercruysse, J.,
Cringoli, G., 2011c. Monitoring drug efﬁcacy against gastrointestinal nematodes
when faecal egg counts are low: do the analytic sensitivity and the formula
matter? Parasitol. Res. 109, 953–957.
Melvin, D.M., Sadun, E.H., Heimlich, C.R., 1956. Comparison of the direct smear and
dilution egg counts in the quantitative determination of hookworm infection.
Am. J. Hyg. 64, 139–148.
Montresor, A., Crompton, D.W.T., Hall, H., Bundy, D.A.P., Savioli, L., 1998. Guidelines
for the evaluation of soil-transmitted helminthiasis and schistosomiasis at
community level. A Guide for Control ProgrammeManagers, WHO/CTD/SIP98.1.
World Health Organization, Geneva.
Paul, M., 2013. eggCounts: Heirarchical modelling of faecal egg counts. Available at:
http://cran.r-project.org/web/packages/eggCounts/index.html (Accessed28.10.13).
Presidente, P.A., 1985. Methods for detection of resistance to anthelmintics. In:
Anderson, N., Waller (Eds.), Resistance in Nematodes to Anthelmintic Drugs.
CSIRO Division of Animal Health, and Australian Wool Corporation, Glebe,
Australia, pp. 13–27.
Stoll, N.R., 1923. Investigations on the control of hookworm disease. XV. An
effective method of counting hookworm eggs in feces. Am. J. Hyg. 3, 59–70.
Torgerson, P.R., Paul, M., Lewis, F.I., 2012. The contribution of simple random
sampling to observed variations in faecal egg counts. Vet. Parasitol. 188, 397–401.
Vercruysse, J., Behnke, J.M., Albonico, M., Ame, S.M., Angebault, C., Bethony, J.M.,
Engels, D., Guillard, B., Nguyen, T.V., Kang, G., Kattula, D., Kotze, A.C., McCarthy,
J.S., Mekonnen, Z., Montresor, A., Periago, M.V., Sumo, L., Tchuenté, L.A., Dang,
T.C., Zeynudin, A., Levecke, B., 2011a. Assessment of the anthelmintic efﬁcacy of
albendazole in school children in seven countries where soil-transmitted
helminths are endemic. PLoS Negl. Trop. Dis. 5, e948.
Vercruysse, J., Albonico, M., Behnke, J.M., Kotze, A.C., Prichard, R.K., McCarthy, J.S.,
Montresor, A., Levecke, B., 2011b. Is anthelmintic resistanceaconcernfor thecontrol
of human soil-transmitted helminths? Int. J. Parasitol. Drugs Drug Res. 1, 14–27.
WHO, 1996. Informal Consultation on Intestinal Parasite Infections:WHODocument
No. WHO/CDC/PI/90.1. World Health Organization, Geneva, Switzerland.
WHO, 2013. Assessing the efﬁcacy of anthelmintic drugs against schistosomiasis
and soil-transmitted helminthiases. WHO Document No. WHO/HTM/NTD/PCT/
2013.4. World Health Organisation, Geneva, Switzerland.
